Athena Philis-Tsimikas, MD
Endocrinology, Diabetes & Metabolism · la Jolla, CANPI 1922105964
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Novo Nordisk AS at 50.9% of the total. Reporting peaked in 2019 at $190,488 and has fallen 73.2% since, to $50,970 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $1754.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$292K
- Novo Nordisk$156K
- Bayer$19K
- Sanofi-aventis U.S. LLC$18K
- Eli Lilly$17K
- Medtronic$17K
- plus $54K from 13 others
Across 4,268 payments — averaging $1273.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$3.3M
- Medtronic$1.1M
- Eli Lilly$551K
- Dexcom, Inc.$372K
- Sequel Med Tech, LLC$68K
- Merck$51K
- plus $16K from 4 others
What the payments were for
- Consulting fees$296,92952%
- Speaking & faculty fees$43,8588%
- Travel & lodging$223,56039%
- Food & beverage$8,8682%
- Education$5350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 106 | $291,918 |
| Novo Nordisk | 90 | $155,859 |
| Bayer | 22 | $19,329 |
| Sanofi-aventis U.S. LLC | 11 | $18,355 |
| Eli Lilly | 19 | $17,337 |
| Medtronic(2 entities) | 19 | $17,332 |
| Boehringer Ingelheim Singapore Pte. Ltd. | 2 | $13,935 |
| Corcept Therapeutics | 13 | $10,469 |
| Dexcom, Inc. | 10 | $9,726 |
| Lilly USA, LLC | 15 | $8,986 |
| Regeneron | 11 | $8,961 |
| Siemens Medical Solutions USA, Inc. | 1 | $1,000 |
| Abbott | 2 | $205 |
| Novartis | 1 | $119 |
| Genentech USA, Inc. | 1 | $101 |
| Tandem Diabetes Care, Inc. | 1 | $56 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Viiv Healthcare Company | 1 | $18 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$43,067
- Victoza$39,590
- Ryzodeg 70/30$18,206
- FIASP$15,204
- TRADJENTA$13,935
- Korlym$9,894
- Kerendia$9,633
- Non-Covered$9,600
- TOUJEO$9,428
- SOLIQUA 100/33$8,852
- Minimed 670G System$8,394
- DEXCOM G6 TRANSMITTER$5,670
- Xultophy 100/3.6$4,291
- NovoLog$3,600
- MOUNJARO$1,966
- DEXCOM G7 GSS (161)$1,785
- DCA Systems Hemoglobin A1c Reagent Kit$1,000
- RYBELSUS$675
- MINIMED 780G$313
- Enlite Sensor$312
How this compares
$573,749 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $129,430 |
| JardianceEmpagliflozin | 42 | $50,816 |
| MounjaroTirzepatide | 20 | $26,169 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $16,974 |
| TrulicityDulaglutide | 12 | $15,333 |
| FarxigaDapagliflozin Propanediol | 14 | $11,161 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,829 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,239 |
| Metformin Hcl | 33 | $522 |
| Glipizide | 11 | $410 |
| Amitriptyline Hcl | 13 | $285 |
| Metformin Hcl ErMetformin Hcl | 13 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $155,859 | $129,43079 claims |
| Lilly USA, LLCMounjaro, Trulicity | $8,986 | $41,50232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in la Jolla
- Daniel Einhornla Jolla$578K
- Matthew Levinela Jolla$134K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.